364 related articles for article (PubMed ID: 26792592)
1. Future therapies for pemphigus vulgaris: Rituximab and beyond.
Huang A; Madan RK; Levitt J
J Am Acad Dermatol; 2016 Apr; 74(4):746-53. PubMed ID: 26792592
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
Kong HH; Prose NS; Ware RE; Hall RP
Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
[TBL] [Abstract][Full Text] [Related]
3. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab).
Morrison LH
J Am Acad Dermatol; 2004 Nov; 51(5):817-9. PubMed ID: 15523367
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in refractory pemphigus vulgaris.
Sorce M; Aricò M; Bongiorno MR
Dermatol Ther; 2008 Jul; 21 Suppl 1():S6-9. PubMed ID: 18727815
[TBL] [Abstract][Full Text] [Related]
5. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
6. [Pemphigus].
Lapeyre-Liénard H; Joly P
Presse Med; 2010 Oct; 39(10):1066-70. PubMed ID: 20817387
[TBL] [Abstract][Full Text] [Related]
7. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases.
Antonucci A; Negosanti M; Tabanelli M; Varotti C
J Dermatolog Treat; 2007; 18(3):178-83. PubMed ID: 17538808
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcomes in a cohort of patients with mucosal-predominant pemphigus vulgaris.
Ojaimi S; O'Connor K; Lin MW; Schifter M; Fulcher DA
Intern Med J; 2015 Mar; 45(3):284-92. PubMed ID: 25534017
[TBL] [Abstract][Full Text] [Related]
9. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).
Dupuy A; Viguier M; Bédane C; Cordoliani F; Blaise S; Aucouturier F; Bonnetblanc JM; Morel P; Dubertret L; Bachelez H
Arch Dermatol; 2004 Jan; 140(1):91-6. PubMed ID: 14732665
[TBL] [Abstract][Full Text] [Related]
10. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of rituximab in refractory pemphigus: a review of case reports.
Allen KJ; Wolverton SE
J Drugs Dermatol; 2007 Sep; 6(9):883-9. PubMed ID: 17941359
[TBL] [Abstract][Full Text] [Related]
12. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris.
Nagel A; Podstawa E; Eickmann M; Müller HH; Hertl M; Eming R
J Invest Dermatol; 2009 Sep; 129(9):2202-10. PubMed ID: 19282839
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus.
Arin MJ; Engert A; Krieg T; Hunzelmann N
Br J Dermatol; 2005 Sep; 153(3):620-5. PubMed ID: 16120153
[TBL] [Abstract][Full Text] [Related]
14. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
El Tal AK; Posner MR; Spigelman Z; Ahmed AR
J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351
[TBL] [Abstract][Full Text] [Related]
15. Successful Treatment of Pemphigus Vulgaris With Ofatumumab.
Rapp M; Pentland A; Richardson C
J Drugs Dermatol; 2018 Dec; 17(12):1338-1339. PubMed ID: 30586270
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
[TBL] [Abstract][Full Text] [Related]
17. Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.
Beyzaee AM; Rahmatpour Rokni G; Patil A; Goldust M
Dermatol Ther; 2021 Jan; 34(1):e14405. PubMed ID: 33051960
[TBL] [Abstract][Full Text] [Related]
18. A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab.
Saleh MA
J Am Acad Dermatol; 2018 Jul; 79(1):97-103. PubMed ID: 29408700
[TBL] [Abstract][Full Text] [Related]
19. Treatment strategies for pemphigus vulgaris in Japan.
Hashimoto T
Expert Opin Pharmacother; 2008 Jun; 9(9):1519-30. PubMed ID: 18518782
[TBL] [Abstract][Full Text] [Related]
20. [Juvenile pemphigus vulgaris].
Janisson-Dargaud D; Reguiaï Z; Perceau G; Eschard C; Bernard P
Ann Dermatol Venereol; 2008 Dec; 135(12):843-7. PubMed ID: 19084695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
